Mercados españoles cerrados

ImmunityBio, Inc. (IBRX)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
5,79-0,19 (-3,18%)
Al cierre: 04:00PM EDT
5,79 0,00 (0,00%)
Después del cierre: 07:53PM EDT

ImmunityBio, Inc.

3530 John Hopkins Court
San Diego, CA 92121
United States
844 696 5235
https://immunitybio.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo628

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.Executive Chairman of the Board and Global Chief Scientific & Medical Officer865,34kN/A1953
Mr. Richard Gerald AdcockPresident, CEO & Director1,16MN/A1969
Mr. David C. SachsChief Financial Officer824,62kN/A1978
Dr. Barry J. Simon M.D.Chief Corporate Affairs Officer & DirectorN/AN/A1965
Dr. Leonard S. Sender M.D.Chief Operating OfficerN/AN/AN/A
Ms. Regan J. LauerChief Accounting OfficerN/AN/A1970
Dr. Enrique Diloné Ph.D., RACChief Technology OfficerN/AN/A1967
Mr. Jason R. LiljestromGeneral Counsel & Corporate SecretaryN/AN/A1983
Ms. Sarah SingletonChief Communications Officer & Head of Patient AdvocacyN/AN/AN/A
Dr. Sandeep K. Reddy M.D.Chief Medical OfficerN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de ImmunityBio, Inc., a día 1 de julio de 2024, es 8. Las puntuaciones base son Auditoría: 7; Tablero: 9; Derechos de los accionistas: 6; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.